Dynamin 1 depletion and memory deficits in rats treated with Aβ and cerebral ischemia

Journal of Neuroscience Research

Volumn 88, Issue 9, 2010, Pages 1908-1917

  Watanabe, Takuya ^a   Iwasaki, Katsunori ^a   Takasaki, Kotaro ^a   Yamagata, Norito ^a   Fujino, Mutsumi ^a   Nogami, Ai ^a   Ii, Miyuki ^a   Katsurabayashi, Shutaro ^a   Mishima, Kenichi ^a   Fujiwara, Michihiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Dynamin 1; Memory; Synaptic dysfunction

Indexed keywords

AMYLOID BETA PROTEIN; DIMER; DYNAMIN I; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLIGOMER; PENICILLIN G; SYNAPTOBREVIN; SYNAPTOPHYSIN; TETRAMER;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; EXPERIMENTAL STUDY; HIPPOCAMPUS; MALE; MEMORY DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; RAT; SYNAPSE VESICLE;

AMYLOID BETA-PROTEIN; ANIMALS; DYNAMIN I; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; ISCHEMIC ATTACK, TRANSIENT; MALE; MAZE LEARNING; MEMANTINE; MEMORY DISORDERS; PC12 CELLS; PEPTIDE FRAGMENTS; PROTEIN MULTIMERIZATION; R-SNARE PROTEINS; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTOPHYSIN;

EID: 77953523944     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22346     Document Type: Article

References (49)

1. Bannerman DM, Matthews P, Deacon RM, Rawlins JN. 2004. Medial septal lesions mimic effects of both selective dorsal and ventral hippocampal lesions. Behav Neurosci 118:1033-1041.
2. Bejar C, Wang RH, Weinstock M. 1999. Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur J Pharmacol 383:231-240.
3. Benveniste H, Drejer J, Schousboe A, Diemer NH. 1984. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 43:1369-1374.
4. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL. 1995. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 64:749-760.
5. Clark SG, Shurland DL, Meyerowitz EM, Bargmann CI, van der Bliek AM. 1997. A dynamin GTPase mutation causes a rapid and reversible temperature-inducible locomotion defect in C. elegans. Proc Natl Acad Sci USA 94:10438-10443. (Pubitemid 127642611)
6. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. 2005. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8:79-84.
7. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ. 2002. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277:32046-32053.
8. Damke H, Baba T, Warnock DE, Schmid SL. 1994. Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J Cell Biol 127:915-934.
9. Davies P, Maloney AJ. 1976. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 12:1403. (Pubitemid 8004505)
10. DeKosky ST, Scheff SW. 1990. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 27:457-464.
11. Dornan WA, McCampbell AR, Tinkler GP, Hickman LJ, Bannon AW, Decker MW, Gunther KL. 1997. Comparison of site specific injections into the basal forebrain on water maze and radial arm maze performance in the male rat after immunolesioning with 192 IgG saporin. Behav Brain Res 86:181-189.
12. Drejer J, Benveniste H, Diemer NH, Schousboe A. 1985. Cellular origin of ischemia-induced glutamate release from brain tissue in vivo and in vitro. J Neurochem 45:145-151.
13. Ferguson SM, Brasnjo G, Hayashi M, Wölfel M, Collesi C, Giovedi S, Raimondi A, Gong LW, Ariel P, Paradise S, O'Toole E, Flavell R, Cremona O, Miesenböck G, Ryan TA, De Camilli P. 2007. A selective activity-dependent requirement for dynamin 1 in synaptic vesicle endocytosis. Science 316:570-574.
14. Glabe CG. 2004. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem Sci 29:542-547.
15. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ. 1999. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19:8876-8884. (Pubitemid 30226709)
16. Hasselmo ME. 2006. The role of acetylcholine in learning and memory. Curr Opin Neurobiol 16:710-715.
17. Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, Staufenbiel M, Noda Y, Yamaguchi H, Nabeshima T, Saido TC, Iwata N. 2006. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem 281:17941-17951.
18. Iwasaki K, Egashira N, Hatip-Al-Khatib I, Akiyoshi Y, Arai T, Takagaki Y, Watanabe T, Mishima K, Fujiwara M. 2006. Cerebral ischemia combined with beta-amyloid impairs spatial memory in the eight-arm radial maze task in rats. Brain Res 1097:216-223.
19. Jahn R, Schiebler W, Ouimet C, Greengard P. 1985. A 38,000-dalton membrane protein (p38) present in synaptic vesicles. Proc Natl Acad Sci USA 82:4137-4141.
20. Kása P, Rakonczay Z, Gulya K. 1997. The cholinergic system in Alzheimer's disease. Prog Neurobiol 52:511-535.
21. Kelly BL, Ferreira A. 2006. Beta-amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J Biol Chem 281:28079-28089.
22. Kelly BL, Vassar R, Ferreira A. 2005. Beta-amyloid-induced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease. J Biol Chem 280:31746-31753.
23. King DL, Arendash GW. 2002. Maintained synaptophysin immunoreactivity in Tg2576 transgenic mice during aging: correlations with cognitive impairment. Brain Res 926:58-68.
24. Lorenzo A, Yankner BA. 1994. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 91:12243-12247.
25. Lorenzo A, Yankner BA. 1996. Amyloid fibril toxicity in Alzheimer's disease and diabetes. Ann NY Acad Sci 777:89-95. (Pubitemid 26149175)
26. McDonald MP, Dahl EE, Overmier JB, Mantyh P, Cleary J. 1994. Effects of an exogenous beta-amyloid peptide on retention for spatial learning. Behav Neural Biol 62:60-67. (Pubitemid 2098037)
27. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. 1999. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46:860-866.
28. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G. 2002. Neuro-protection by memantine against neurodegeneration induced by beta-amyloid (1-40). Brain Res 958:210-221.
29. Navone F, Jahn R, Di Gioia G, Stukenbrok H, Greengard P, De Camilli P. 1986. Protein p38: an integral membrane protein specific for small vesicles of neurons and neuroendocrine cells. J Cell Biol 103:2511-2527.
30. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ. 1995. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 270:9564-9570.
31. Qiu Z, Gruol DL. 2003. Interleukin-6, beta-amyloid peptide and NMDA interactions in rat cortical neurons. J Neuroimmunol 139:51-57.
32. Sabbagh MN, Corey-Bloom J, Tiraboschi P, Thomas R, Masliah E, Thal LJ. 1999. Neurochemical markers do not correlate with cognitive decline in the Lewy body variant of Alzheimer disease. Arch Neurol 56:1458-1461.
33. Sakaba T, Stein A, Jahn R, Neher E. 2005. Distinct kinetic changes in neurotransmitter release after SNARE protein cleavage. Science 309:491-494.
34. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S. 1996. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2:864-70.
35. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C. 1992. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359:832-835.
36. Schoch S, Deák F, Königstorfer A, Mozhayeva M, Sara Y, Südhof TC, Kavalali ET. 2001. SNARE function analyzed in synaptobrevin/VAMP knockout mice. Science 294:1117-1122.
37. Selkoe DJ. 2002. Alzheimer's disease is a synaptic failure. Science 298:789-791.
38. Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA, Holzman TF. 1994. Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J 67:1216-1228.
39. Song MS, Rauw G, Baker GB, Kar S. 2008. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Eur J Neurosci 28:1989-2002.
40. Sweeney WA, Luedtke J, McDonald MP, Overmier JB. 1997. Intrahippocampal injections of exogenous beta-amyloid induce postdelay errors in an eight-arm radial maze. Neurobiol Learn Mem 68:97-101.
41. Sze CI, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ. 2000. Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's disease brains. J Neurol Sci 175:81-90.
42. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. 1991. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572-580.
43. Tiraboschi P, Hansen LA, Alford M, Masliah E, Thal LJ, Corey-Bloom J. 2000. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology 55:1278-1283.
44. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. 2002a. Amyloid-beta oligomers: their production toxicity and therapeutic inhibition. Biochem Soc Trans 30:552-557.
45. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. 2002b. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539.
46. Watanabe T, Iwasaki K, Ishikane S, Naitou T, Yoshimitsu Y, Yamagata N, Ozdemir MB, Takasaki K, Egashira N, Mishima K, Fujiwara M. 2008. Spatial memory impairment without apoptosis induced by the combination of beta-amyloid oligomers and cerebral ischemia is related to decreased acetylcholine release in rats. J Pharmacol Sci 106:84-91.
47. Wiedenmann B, Franke WW. 1985. Identification and localization of synaptophysin an integral membrane glycoprotein of Mr 38000 characteristic of presynaptic vesicles. Cell 41:1017-1028. (Pubitemid 15243405)
48. Yao PJ. 2004. Synaptic frailty and clathrin-mediated synaptic vesicle trafficking in Alzheimer's disease. Trends Neurosci 27:24-29.
49. Yao PJ, Zhu M, Pyun EI, Brooks AI, Therianos S, Meyers VE, Coleman PD. 2003. Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol Dis 12:97-109.